High levels of Fas ligand and MHC class II in the absence of CD80 or CD86 expression and a decreased CD4+ T cell infiltration, enables murine skin tumours to progress

Cancer Immunology, Immunotherapy

Volumn 52, Issue 6, 2003, Pages 396-402

  Byrne, Scott N ^a   Halliday, Gary M ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

CD4 T cells; Costimulation; FasL; Tumour immunity; Tumour progression

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TARGET CELL; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME;

EID: 0038620168     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0380-0     Document Type: Article

References (28)

1. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS (1993) Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177:165
2. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH (1993) Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A 90:5687
3. Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S (1995) Major histocompatibility complex class II + B7-1 + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619
4. Chen L, McGowan P, Ashe S, Johnston JV, Hellstrom I, Hellstrom KE (1994) B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420
5. Yang G, Hellstrom KE, Hellstrom I, Chen L (1995) Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 154:2794
6. Yang S, Vervaert CE, Seigler HF, Darrow TL (1999) Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. Gene Ther 6:253
7. Holzmann B, Brocker EB, Lehmann JM, Ruiter DJ, Sorg C, Riethmuller G, Johnson JP (1987) Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 39:466
8. Brocker EB, Suter L, Bruggen J, Ruiter DJ, Macher E, Sorg C (1985) Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer 36:29
9. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363
10. Nishimatsu H, Takeuchi T, Ueki T, Kajiwara T, Moriyama N, Ishida T, Li BX, Kakizoe T, Kitamura T (1999) CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol Immunother 48:56
11. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP (1999) Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 59:59
12. Restifo NP (2000) Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 6:493
13. Tada Y, O-Wang J, Takiguchi Y, Tatsumi K, Kuriyama T, Okada S, Tokuhisa T, Sakiyama S, Tagawa M (2002) A novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol 169:2241
14. Cavanagh LL, Halliday GM (1996) Dendritic epidermal T cells in ultraviolet-irradiated skin enhance skin tumor growth by inhibiting CD4+ T-cell-mediated immunity. Cancer Res 56:2607
15. Patel A, Halliday GM, Cooke BE, Barnetson RS (1994) Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma. Br J Dermatol 131:789
16. Hunt MJ, Halliday GM, Weedon D, Cooke BE, Barnetson RS (1994) Regression in basal cell carcinoma: an immunohistochemical analysis. Br J Dermatol 130:1
17. Glew SS, Duggan-Keen M, Cabrera T, Stern PL (1992) HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res 52:4009
18. Esteban F, Ruiz-Cabello F, Concha A, Perez-Ayala M, Sanchez-Rozas JA, Garrido F (1990) HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx. Clin Exp Metastasis 8:319
19. Halliday GM, Patel A, Hunt MJ, Tefany FJ, Barnetson RS (1995) Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4 + T cells. World J Surg 19:352
20. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357
21. Aruga E, Tanigawa K, Aruga A, Arai H, Smith JW, Nickoloff BJ, Nabel GJ, Chang AE (2000) CD95-mediated tumor recognition by CD4(+) effector cells in a murine mammary model. J Immunother 23:225
22. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 96:8633
23. Eberl LP, Guillou L, Saraga E, Schroter M, French LE, Tschopp J, Juillerat-Jeanneret L (1999) Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int J Cancer 81:772
24. Terheyden P, Siedel C, Merkel A, Kampgen E, Brocker EB, Becker J C (1999) Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. J Invest Dermatol 112:899
25. Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B (2000) The tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol 164:5023
26. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, Stringaro A, Molinari A, Arancia G, Gentile M, Parmiani G, Fais S (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195:1303
27. McAdam AJ, Schweitzer AN, Sharpe AH (1998) The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 165:231
28. Catlett IM, Xie P, Hostager BS, Bishop GA (2001) Signaling through MHC class II molecules blocks CD95-induced apoptosis. J Immunol 166:6019